These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 21079154)

  • 41. Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma.
    Bauer K; Skoetz N; Monsef I; Engert A; Brillant C
    Cochrane Database Syst Rev; 2011 Aug; (8):CD007941. PubMed ID: 21833963
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials.
    Sieniawski M; Reineke T; Josting A; Nogova L; Behringer K; Halbsguth T; Fuchs M; Diehl V; Engert A
    Ann Oncol; 2008 Oct; 19(10):1795-801. PubMed ID: 18544558
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early chemotherapy de-escalation strategy in patients with advanced-stage Hodgkin lymphoma with negative positron emission tomography scan after 2 escalated BEACOPP cycles.
    Długosz-Danecka M; Szmit S; Kocurek A; Koźlik P; Giza A; Zimowska-Curyło D; Małkowski B; Sowa-Staszczak A; Kużdżał J; Jurczak W
    Pol Arch Intern Med; 2019 Apr; 129(4):259-266. PubMed ID: 30945698
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
    Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
    J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study.
    Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):9-10. PubMed ID: 27007004
    [No Abstract]   [Full Text] [Related]  

  • 46. Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis.
    Fosså A; Fiskvik IH; Kolstad A; Lauritzsen GF; Aurlien E; Blystad AK; Hole KH; Ikonomou IM; Holte H
    Ann Oncol; 2012 May; 23(5):1254-1259. PubMed ID: 21926399
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin's lymphoma.
    Niitsu N; Okamoto M; Tomita N; Aoki S; Tamaru J; Miura I; Hirano M
    Leuk Lymphoma; 2006 Sep; 47(9):1908-14. PubMed ID: 17065005
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial.
    von Tresckow B; Plütschow A; Fuchs M; Klimm B; Markova J; Lohri A; Kral Z; Greil R; Topp MS; Meissner J; Zijlstra JM; Soekler M; Stein H; Eich HT; Mueller RP; Diehl V; Borchmann P; Engert A
    J Clin Oncol; 2012 Mar; 30(9):907-13. PubMed ID: 22271480
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current clinical trials for the treatment of advanced-stage Hodgkin's disease: BEACOPP.
    Franklin J; Diehl V
    Ann Oncol; 2002; 13 Suppl 1():98-101. PubMed ID: 12078913
    [TBL] [Abstract][Full Text] [Related]  

  • 50. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group.
    Diehl V; Sieber M; Rüffer U; Lathan B; Hasenclever D; Pfreundschuh M; Loeffler M; Lieberz D; Koch P; Adler M; Tesch H
    Ann Oncol; 1997 Feb; 8(2):143-8. PubMed ID: 9093722
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma.
    Avigdor A; Bulvik S; Levi I; Dann EJ; Shemtov N; Perez-Avraham G; Shimoni A; Nagler A; Ben-Bassat I; Polliack A
    Ann Oncol; 2010 Jan; 21(1):126-32. PubMed ID: 19608615
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Effectiveness and toxicity of MOPP, ABVD, BEACOPP chemotherapy in first-diagnosed Hodgkin lymphoma with a poor prognosis].
    Filatova LV; Plotnikova AA; Gershanovich ML; Semiglazova TIu
    Vopr Onkol; 2013; 59(2):59-65. PubMed ID: 23814851
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cyclophosphamide-based, seven-drug hybrid and low-dose involved field radiation for the treatment of childhood and adolescent Hodgkin disease.
    Hamilton VM; Norris C; Bunin N; Goldwein JW; Bunin GR; Lange B; Meadows AT
    J Pediatr Hematol Oncol; 2001 Feb; 23(2):84-8. PubMed ID: 11216711
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
    Kedmi M; Apel A; Davidson T; Levi I; Dann EJ; Polliack A; Ben-Bassat I; Nagler A; Avigdor A
    Acta Haematol; 2016; 135(3):156-61. PubMed ID: 26588173
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.
    Advani RH; Hong F; Fisher RI; Bartlett NL; Robinson KS; Gascoyne RD; Wagner H; Stiff PJ; Cheson BD; Stewart DA; Gordon LI; Kahl BS; Friedberg JW; Blum KA; Habermann TM; Tuscano JM; Hoppe RT; Horning SJ
    J Clin Oncol; 2015 Jun; 33(17):1936-42. PubMed ID: 25897153
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fertility in young patients following treatment for Hodgkin's lymphoma: a single center survey.
    Boltežar L; Pintarić K; Jezeršek Novaković B
    J Assist Reprod Genet; 2016 Mar; 33(3):325-333. PubMed ID: 26678493
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial.
    Mauz-Körholz C; Landman-Parker J; Balwierz W; Ammann RA; Anderson RA; Attarbaschi A; Bartelt JM; Beishuizen A; Boudjemaa S; Cepelova M; Claviez A; Daw S; Dieckmann K; Fernández-Teijeiro A; Fosså A; Gattenlöhner S; Georgi T; Hjalgrim LL; Hraskova A; Karlén J; Kluge R; Kurch L; Leblanc T; Mann G; Montravers F; Pears J; Pelz T; Rajić V; Ramsay AD; Stoevesandt D; Uyttebroeck A; Vordermark D; Körholz D; Hasenclever D; Wallace WH
    Lancet Oncol; 2022 Jan; 23(1):125-137. PubMed ID: 34895479
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sarcoidosis following escalated BEACOPP chemotherapy for stage IV Hodgkin lymphoma.
    Cho KK; Lyes SM; Shetty A
    Intern Med J; 2019 Apr; 49(4):547-548. PubMed ID: 30957369
    [No Abstract]   [Full Text] [Related]  

  • 60. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.
    Engert A; Haverkamp H; Kobe C; Markova J; Renner C; Ho A; Zijlstra J; Král Z; Fuchs M; Hallek M; Kanz L; Döhner H; Dörken B; Engel N; Topp M; Klutmann S; Amthauer H; Bockisch A; Kluge R; Kratochwil C; Schober O; Greil R; Andreesen R; Kneba M; Pfreundschuh M; Stein H; Eich HT; Müller RP; Dietlein M; Borchmann P; Diehl V; ; ;
    Lancet; 2012 May; 379(9828):1791-9. PubMed ID: 22480758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.